Aimmune Therapeutics Inc (AIMT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen George Dilly
Employees:
215
8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA 94005-1884
(650) 614-5220

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy (CODIT) system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Data derived from most recent annual or quarterly report
Market Cap 2.257 Billion Shares Outstanding65.45 Million Avg 30-day Volume 1.626 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.4
Price to Revenue1902.038 Debt to Equity0.7309 EBITDA-277.108 Million
Price to Book Value6.0808 Operating Margin-49193.3913 Enterprise Value907.054 Million
Current Ratio7.526 EPS Growth-0.207 Quick Ratio7.302
1 Yr BETA 0.9963 52-week High/Low 0.0 / Profit Margin-49918.087
Operating Cash Flow Growth-24.635 Free Cash Flow to Firm (FCFF) TTM -197.999 Million Free Cash Flow to Equity (FCFE) TTM-201.997 Million
Altman Z-Score-1.4561
View SEC Filings from AIMT instead.

View recent insider trading info

Aimmune Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AIMT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AIMT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2020-10-15 by SOCIETE DES PRODUITS NESTLE S.A.
  • 4: filed on 2020-10-14 by OXTOBY ANDREW
  • 4: filed on 2020-10-14 by SHEEHY DOUGLAS T.
  • 4: filed on 2020-10-14 by DALLAS JAYSON DONALD ALEXANDER
  • 4: filed on 2020-10-14 by BEHAR GREGORY
  • 4: filed on 2020-10-14 by BJERKHOLT ERIC
  • 4: filed on 2020-10-14 by IWICKI MARK T
  • 4: filed on 2020-10-14 by ENRIGHT PATRICK G
  • 4: filed on 2020-10-14 by ADELMAN DANIEL C MD
  • 4: filed on 2020-10-14 by FALBERG KATHRYN E

    • Events (8k)

  • 8-K: filed on 2020-10-19:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-28:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2020-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-02-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-01-31:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-12-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-15:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2019-09-16:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-06-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BEHAR GREGORY

    • Director
    		 No longer subject to file 2020-10-13 0

    SOCIETE DES PRODUITS NESTLE S.A.

    • 10% Owner
    		 80,097,147 2020-10-13 0

    BJERKHOLT ERIC CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-10 0

    FALBERG KATHRYN E

    • Director
    		 No longer subject to file 2020-10-10 0

    ADELMAN DANIEL C MD CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-10 0

    MCDADE MARK

    • Director
    		 No longer subject to file 2020-10-10 0

    ENRIGHT PATRICK G

    • Director
    		 No longer subject to file 2020-10-10 0

    IWICKI MARK T

    • Director
    		 No longer subject to file 2020-10-10 0

    SHEEHY DOUGLAS T. SEE REMARKS

    • Officer
    		 No longer subject to file 2020-10-10 0

    HAUMANN BRETT K

    • Director
    		 No longer subject to file 2020-10-10 0

    SELTZER STACEY DENENBERG

    • Director
    		 No longer subject to file 2020-10-10 0

    DALLAS JAYSON DONALD ALEXANDER PRESIDENT AND CEO

    • Officer
    • Director
    		 No longer subject to file 2020-10-10 0

    OXTOBY ANDREW CHIEF COMMERCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-10 0

    SOCIETE DES PRODUITS NESTLE S.A.

    NESTLE SA

    • 10% Owner
    		 26,505,494 2020-02-07 0

    ROZENMAN MARY M. SEE REMARKS

    • Officer
    		 13,878 2019-12-31 0

    NESTLE HEALTH SCIENCE US HOLDINGS, INC.

    SOCIETE DES PRODUITS NESTLE S.A.

    NESTLE SA

    NIMCO US, INC.

    NESTLE US HOLDCO, INC.

    • 10% Owner
    		 11,727,113 2018-12-31 0

    BARROWCLIFFE SUSAN E. GENERAL MANAGER, EUROPE

    • Officer
    		 9,375 2018-11-19 0

    DILLY STEPHEN GEORGE PRESIDENT AND CEO

    • Officer
    • Director
    		 447,008 2018-06-11 0

    KNAPP JEFFREY H CHIEF OPERATING OFFICER

    • Officer
    		 12,151 2018-03-04 0

    NESTLE HEALTH SCIENCE US HOLDINGS, INC.

    NESTLE SA

    NIMCO US, INC.

    • 10% Owner
    		 11,727,113 2018-02-26 0

    TAMMENOMS BAKKER JULIET

    • 10% Owner
    		 6,029,785 2018-02-22 0

    DESOUZA WARREN L. CHIEF FINANCIAL OFFICER

    • Officer
    		 324,475 2017-04-03 0

    LONGITUDE CAPITAL PARTNERS II, LLC

    TAMMENOMS BAKKER JULIET

    LONGITUDE VENTURE PARTNERS II, L.P.

    • 10% Owner
    		 6,020,410 2016-11-29 0

    FORESITE CAPITAL MANAGEMENT II, LLC

    FORESITE CAPITAL FUND II, L.P.

    FORESITE CAPITAL MANAGEMENT III, LLC

    FORESITE CAPITAL FUND III, L.P.

    TANANBAUM JAMES B.

    • 10% Owner
    		 4,902,920 2016-08-18 0

    LONGITUDE CAPITAL PARTNERS II, LLC

    LONGITUDE VENTURE PARTNERS II, L.P.

    TAMMENOMS BAKKER JULIET

    ENRIGHT PATRICK G

    • 10% Owner
    		 7,513,134 2016-03-29 0

    ELFONT ROBERT MYLES CHIEF MEDICAL OFFICER

    • Officer
    		 299,002 2016-02-26 0

    FORESITE CAPITAL MANAGEMENT II, LLC

    FORESITE CAPITAL FUND II, L.P.

    TANANBAUM JAMES B.

    • 10% Owner
    		 0 2015-08-05 0

    RAFF HOWARD V. CHIEF OPERATING OFFICER

    • Officer
    		 428,575 2015-08-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund AIMT -112.0 shares, $-1615.04 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund AIMT -228.0 shares, $-3287.76 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments